DK0430190T3 - Hidtil ukendte tricykliske forbindelser - Google Patents

Hidtil ukendte tricykliske forbindelser

Info

Publication number: DK0430190T3
Authority: DK; Denmark
Prior art keywords: alkyl; amino; alkoxy; halogen; optionally substituted
Prior art date: 1989-11-28

Application number

DK90122689.4T

Other languages

English (en)

Inventor

Jacob Berger

Robin D Clark

Richard M Eglen

William L Smith

Klaus K Weinhardt

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-11-28

Filing date

1990-11-27

Publication date

1995-08-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0430190(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-11-27 Application filed by Syntex Inc filed Critical Syntex Inc

1995-08-21 Application granted granted Critical

1995-08-21 Publication of DK0430190T3 publication Critical patent/DK0430190T3/da

Links

150000001875 compounds Chemical class 0.000 title abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 6
125000003545 alkoxy group Chemical group 0.000 abstract 3
229910052736 halogen Inorganic materials 0.000 abstract 3
150000002367 halogens Chemical class 0.000 abstract 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
-1 nitro, amino, amino carbonyl Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
125000001589 carboacyl group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
125000002541 furyl group Chemical group 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000000168 pyrrolyl group Chemical group 0.000 abstract 1
239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
125000001544 thienyl group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Nutrition Science (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)

DK90122689.4T 1989-11-28 1990-11-27 Hidtil ukendte tricykliske forbindelser DK0430190T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US44208289A	1989-11-28	1989-11-28

Publications (1)

Publication Number	Publication Date
DK0430190T3 true DK0430190T3 (da)	1995-08-21

Family

ID=23755479

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK90122689.4T DK0430190T3 (da)	1989-11-28	1990-11-27	Hidtil ukendte tricykliske forbindelser

Country Status (23)

Country	Link
US (1)	US5202333A (da)
EP (1)	EP0430190B1 (da)
JP (1)	JPH0662607B2 (da)
KR (1)	KR970007917B1 (da)
AT (1)	ATE124698T1 (da)
AU (1)	AU642178B2 (da)
BR (1)	BR1100680A (da)
CA (1)	CA2030718C (da)
DE (2)	DE122005000027I2 (da)
DK (1)	DK0430190T3 (da)
ES (1)	ES2075121T3 (da)
FI (1)	FI98367C (da)
HK (1)	HK36097A (da)
HU (1)	HU218654B (da)
IE (1)	IE68434B1 (da)
IL (2)	IL110622A (da)
LU (1)	LU91162I2 (da)
NL (1)	NL300194I1 (da)
NO (2)	NO175309C (da)
NZ (1)	NZ236225A (da)
PL (3)	PL166277B1 (da)
PT (1)	PT96001B (da)
ZA (1)	ZA909529B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ236225A (en) *	1989-11-28	1992-09-25	Syntex Inc	Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions
US5491148A (en) *	1991-04-26	1996-02-13	Syntex (U.S.A.) Inc.	Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
EP1082959A1 (en) *	1991-09-20	2001-03-14	Glaxo Group Limited	NK1 Antagonists for the treatment of depression
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) *	1992-07-08	2004-01-06	Nektar Therapeutics	Compositions and methods for the pulmonary delivery of aerosolized medicaments
ATE220327T1 (de) *	1992-09-29	2002-07-15	Inhale Therapeutic Syst	Pulmonale abgabe von aktiven fragmenten des parathormons
ES2218543T3 (es) *	1994-03-07	2004-11-16	Nektar Therapeutics	Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US20030113273A1 (en) *	1996-06-17	2003-06-19	Patton John S.	Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) *	1994-04-13	1998-04-29	Quadrant Holdings Cambridge	Pharmaceutical compositions
NZ285664A (en) *	1994-05-18	1998-07-28	Inhale Therapeutic Syst	Dry powder interferon composition adapted for pulmonary delivery
US5567818A (en) *	1994-07-08	1996-10-22	Syntex (U.S.A.) Inc.	Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) *	1994-07-26	1996-04-23	Syntex (U.S.A.) Inc.	Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) *	1994-07-28	1996-02-20	Syntex (U.S.A.) Inc.	2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en)	1994-12-02	2001-09-18	Quandrant Holdings Cambridge Limited	Solid dose delivery vehicle and methods of making same
US5723103A (en) *	1994-12-09	1998-03-03	Vanderbilt University	Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) *	1997-07-14	2003-02-20	Robert Platz	Methods and compositions for the dry powder formulation of interferon
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
DE60042446D1 (de) *	1999-02-18	2009-08-06	Novasearch Ag	Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7442388B2 (en)	2000-05-10	2008-10-28	Weers Jeffry G	Phospholipid-based powders for drug delivery
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US20050042194A1 (en) *	2000-05-11	2005-02-24	A.P. Pharma, Inc.	Semi-solid delivery vehicle and pharmaceutical compositions
WO2001087305A2 (en) *	2000-05-18	2001-11-22	Glaxo Group Limited	Method for treating functional dyspepsia using alosetron
JP2004525109A (ja)	2001-02-15	2004-08-19	キング・ファーマシューティカルズ・インコーポレイティッド	安定化された甲状腺ホルモン医薬組成物、及びその製法
US7101569B2 (en)	2001-08-14	2006-09-05	Franz G Andrew	Methods of administering levothyroxine pharmaceutical compositions
US7368102B2 (en)	2001-12-19	2008-05-06	Nektar Therapeutics	Pulmonary delivery of aminoglycosides
WO2003072578A1 (en) *	2002-02-20	2003-09-04	Pharmacia & Upjohn Company	Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US20030187017A1 (en) *	2002-11-14	2003-10-02	Mangel Allen Wayne	Method for treating functional dyspepsia
JP5690461B2 (ja) *	2002-11-15	2015-03-25	ヘルシンヘルスケアソシエテアノニム	化学療法誘導嘔吐を治療するためのパロノセトロン
JO2735B1 (en) *	2003-01-30	2013-09-15	هيلسين هيلث كير أس ايه.	Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en)	2003-01-30	2013-12-03	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
TWI355936B (en)	2003-02-18	2012-01-11	Helsinn Healthcare Sa	Uses of palonosetron hydrochloride
US20060167072A1 (en) *	2004-01-30	2006-07-27	Helsinn Healthcare Sa	Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) *	2005-02-23	2007-09-12	重庆医药工业研究院有限责任公司	一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) *	2005-06-22	2007-02-08	Nektar Therapeutics	Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) *	2006-06-29	2008-01-03	Transcept Pharmaceuticals, Inc.	Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) *	2006-08-30	2013-12-24	Dr. Reddy's Laboratories Limited	Process for the purification of palonosetron or its salt
HRPK20100281B3 (hr) *	2006-10-23	2012-01-31	Sicor Inc.	Kristalni oblici palonosetron hidroklorida
CA2666512C (en) *	2006-10-24	2014-05-27	Helsinn Healthcare S.A.	Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
JP2010512333A (ja) *	2006-12-07	2010-04-22	ヘルシンヘルスケアソシエテアノニム	塩酸パロノセトロンの結晶及び非晶質形
WO2008146283A2 (en) *	2007-05-29	2008-12-04	Chemagis Ltd.	Novel palonosetron salts and processes for preparation and purification thereof
US20090227623A1 (en) *	2007-09-15	2009-09-10	Protia, Llc	Deuterium-enriched palosetron
CN101157691B (zh) *	2007-10-18	2011-01-12	杭州九源基因工程有限公司	一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es) *	2007-12-13	2010-02-03	Glenmark Generics Ltd	Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (en) *	2008-01-11	2009-07-16	Natco Pharma Limited	Novel crystalline forms of palonosetron hydrochloride
WO2009136405A1 (en) *	2008-05-05	2009-11-12	Natco Pharma Limited	High purity palonosetron base and its solid state characteristics
US20100048607A1 (en) *	2008-08-25	2010-02-25	Chandrashekhar Kocherlakota	Formulations comprising palonosetron
US20100099701A1 (en) *	2008-10-20	2010-04-22	Auspex Pharmaceuticals, Inc.	Isoquinolinone modulators of 5-ht3 receptors
EP2364312A4 (en) *	2008-11-11	2012-05-02	Reddys Lab Ltd Dr	SYNTHESIS OF CRYSTALLINE PALONOSETRON CHLORHYDRATE
WO2010077669A2 (en)	2008-12-08	2010-07-08	Teva Pharmaceutical Industries Ltd.	Palonosetron formulation
JP2012512163A (ja) *	2008-12-11	2012-05-31	エーピーファーマ，インコーポレイテッド	ポリオルトエステルおよびそれらの製剤の安定性を高めるための方法
CN101849904A (zh) *	2009-04-03	2010-10-06	南京长澳医药科技有限公司	一种帕洛诺司琼注射液及其制备方法
CN101851233B (zh) *	2009-04-03	2013-03-06	四川滇虹医药开发有限公司	盐酸帕洛诺司琼和其前体化合物及制备
US20100298397A1 (en) *	2009-05-19	2010-11-25	Singh Nikhilesh N	Method of treatment of obsessive compulsive disorder with ondansetron
ES2664599T3 (es)	2009-05-20	2018-04-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antagonistas del receptor 5-HT3 de serotonina para uso en el tratamiento de trastornos vestibulares lesionales
EP2253316B1 (en)	2009-05-20	2013-08-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of an inner ear pathology with vestibular deficits
EP2448936A2 (en)	2009-06-30	2012-05-09	Ranbaxy Laboratories Limited	Processes for the preparation of form i and form ii of palonosetron hydrochloride
JP5663572B2 (ja)	2009-07-14	2015-02-04	アルバニーモレキュラーリサーチ，インコーポレイテッド	５−ｈｔ３受容体モジュレーター、その作製方法、およびその使用
WO2011013095A1 (en)	2009-07-31	2011-02-03	Ranbaxy Laboratories Limited	Processes for the preparation of palonosetron
WO2011058427A1 (en) *	2009-11-13	2011-05-19	Helsinn Healthcare S.A.	Palonosetron metabolites
EP2722045B1 (en)	2009-11-18	2016-07-06	Helsinn Healthcare SA	Compositions for treating centrally mediated nausea and vomiting
CN106512010A (zh)	2009-11-18	2017-03-22	赫尔辛医疗股份公司	用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2744497B1 (en)	2011-10-18	2016-04-06	Helsinn Healthcare SA	Therapeutic combinations of netupitant and palonosetron
CN102688185B (zh) *	2012-06-01	2013-07-10	齐鲁制药(海南)有限公司	一种稳定的帕洛诺司琼注射液及其制备方法
MX2016008369A (es)	2013-12-23	2016-12-15	Samyang Biopharmaceuticals	Composicion farmaceutica que incluye palonosetron.
WO2017044693A1 (en)	2015-09-11	2017-03-16	Chase Pharmaceuticals Corporation	Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
PT3435980T (pt) *	2016-06-06	2020-02-21	Helsinn Healthcare Sa	Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
ES3065670T3 (en)	2017-04-24	2026-05-07	Alto Neuroscience Inc	Compositions and method for treating depression
EP3672964A4 (en)	2017-08-21	2021-05-26	Leiutis Pharmaceuticals Pvt. Ltd.	Novel triple combination formulations for antiemetic therapy
KR20250125376A (ko)	2022-12-12	2025-08-21	알프레드 이. 티펜바흐어 게엠베하 운트 ＆ 코. 카게	네투피탄트 및 팔로노세트론을 포함하는 고정 용량 복합제
EP4385497A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en)	2022-12-12	2024-06-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en)	2022-12-12	2024-06-20	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3341528A (en) *	1963-11-07	1967-09-12	Warner Lambert Pharmaceutical	Substituted benzoquinolines
US3896132A (en) *	1969-08-19	1975-07-22	Hoffmann La Roche	Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) *	1980-03-17	1982-01-05	Dynapol	Process for preparing cyclic amides
EP0093488A3 (en) *	1982-03-18	1984-05-23	Beecham Group Plc	Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them
US4571396A (en) *	1984-04-16	1986-02-18	Warner-Lambert Company	Antibacterial agents
AU8325987A (en) *	1986-12-11	1988-06-30	Upjohn Company, The	Antipsychotic amino-polyhydro-benz-(iso)quinolines and intermediates
EP0315390B1 (en) *	1987-11-04	1994-07-20	Beecham Group Plc	Novel 4-oxobenzotriazines and 4-oxoquinazolines
NZ236225A (en) *	1989-11-28	1992-09-25	Syntex Inc	Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions
AU7618991A (en) *	1990-05-14	1991-11-14	Syntex (U.S.A.) Inc.	Novel tricyclic compounds
US5189041A (en) *	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists

1990
- 1990-11-27 NZ NZ236225A patent/NZ236225A/en unknown
- 1990-11-27 JP JP2328764A patent/JPH0662607B2/ja not_active Expired - Fee Related
- 1990-11-27 AT AT90122689T patent/ATE124698T1/de active
- 1990-11-27 DE DE200512000027 patent/DE122005000027I2/de active Active
- 1990-11-27 AU AU66963/90A patent/AU642178B2/en not_active Expired
- 1990-11-27 FI FI905839A patent/FI98367C/fi active Protection Beyond IP Right Term
- 1990-11-27 ES ES90122689T patent/ES2075121T3/es not_active Expired - Lifetime
- 1990-11-27 PL PL90303661A patent/PL166277B1/pl unknown
- 1990-11-27 DK DK90122689.4T patent/DK0430190T3/da active
- 1990-11-27 KR KR1019900019275A patent/KR970007917B1/ko not_active Expired - Lifetime
- 1990-11-27 EP EP90122689A patent/EP0430190B1/en not_active Expired - Lifetime
- 1990-11-27 PL PL90287961A patent/PL166272B1/pl unknown
- 1990-11-27 CA CA002030718A patent/CA2030718C/en not_active Expired - Lifetime
- 1990-11-27 ZA ZA909529A patent/ZA909529B/xx unknown
- 1990-11-27 NO NO905120A patent/NO175309C/no not_active IP Right Cessation
- 1990-11-27 DE DE69020694T patent/DE69020694T2/de not_active Expired - Lifetime
- 1990-11-27 PL PL90303660A patent/PL166267B1/pl unknown
- 1990-11-27 IE IE426990A patent/IE68434B1/en not_active IP Right Cessation
- 1990-11-27 PT PT96001A patent/PT96001B/pt not_active IP Right Cessation
- 1990-11-27 IL IL11062290A patent/IL110622A/en not_active IP Right Cessation
- 1990-11-27 HU HU670/90A patent/HU218654B/hu active Protection Beyond IP Right Term
- 1990-11-27 IL IL9648690A patent/IL96486A/en active Protection Beyond IP Right Term
1991
- 1991-05-22 US US07/704,565 patent/US5202333A/en not_active Expired - Lifetime
1997
- 1997-03-20 HK HK36097A patent/HK36097A/en not_active IP Right Cessation
- 1997-05-08 BR BR1100680-3A patent/BR1100680A/pt active IP Right Grant
2005
- 2005-04-18 LU LU91162C patent/LU91162I2/fr unknown
- 2005-04-20 NL NL300194C patent/NL300194I1/nl unknown
- 2005-09-21 NO NO2005023C patent/NO2005023I2/no unknown

Also Published As

Publication number	Publication date
DE122005000027I2 (de)	2006-03-16
DE69020694D1 (de)	1995-08-10
PT96001A (pt)	1991-09-30
AU6696390A (en)	1991-06-06
NO905120D0 (no)	1990-11-27
EP0430190A2 (en)	1991-06-05
ZA909529B (en)	1992-08-26
US5202333A (en)	1993-04-13
KR970007917B1 (ko)	1997-05-17
PT96001B (pt)	1998-01-30
CA2030718A1 (en)	1991-05-29
ATE124698T1 (de)	1995-07-15
FI905839L (fi)	1991-05-29
NO175309B (no)	1994-06-20
FI98367C (fi)	1997-06-10
EP0430190A3 (en)	1992-01-22
NZ236225A (en)	1992-09-25
CA2030718C (en)	1998-05-12
NO905120L (no)	1991-05-29
HU218654B (hu)	2000-10-28
FI98367B (fi)	1997-02-28
IL110622A (en)	1995-03-30
NL300194I2 (nl)	2005-07-01
NO175309C (no)	1994-09-28
PL166267B1 (pl)	1995-04-28
HU907660D0 (en)	1991-06-28
KR910009699A (ko)	1991-06-28
AU642178B2 (en)	1993-10-14
IL96486A0 (en)	1991-08-16
PL166272B1 (pl)	1995-04-28
EP0430190B1 (en)	1995-07-05
PL287961A1 (en)	1991-12-02
FI905839A0 (fi)	1990-11-27
IL96486A (en)	1995-03-30
HUT56368A (en)	1991-08-28
NL300194I1 (nl)	2005-07-01
HK36097A (en)	1997-03-27
NO2005023I2 (no)	2009-10-05
ES2075121T3 (es)	1995-10-01
DE122005000027I1 (de)	2005-08-04
PL166277B1 (pl)	1995-04-28
BR1100680A (pt)	2000-02-08
IE68434B1 (en)	1996-06-12
NO2005023I1 (no)	2005-10-03
IE904269A1 (en)	1991-06-05
DE69020694T2 (de)	1996-01-18
LU91162I2 (fr)	2005-06-20
JPH03176486A (ja)	1991-07-31
JPH0662607B2 (ja)	1994-08-17

Publication	Publication Date	Title
BR1100680A (pt)	2000-02-08	Antagonistas tricìclos de receptores de 5-ht3
KR900012911A (ko)	1990-09-03	흥분성 아미노산 수용기 길항질 화합물
EA200000592A1 (ru)	2000-12-25	Азаполициклические соединения, конденсированные с арилом
EA200200873A1 (ru)	2003-04-24	Новые пиперазиновые производные
EA200000391A1 (ru)	2000-12-25	Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ATE219766T1 (de)	2002-07-15	N-acylierte 4-aminopiperidin derivate als aktive bestandteile von peripher gefässerweiternden wikstoffen
EA199800794A1 (ru)	1999-04-29	Новые производные арилглициламида, способ их получения и фармацевтическая композиция, содержащая эти соединения
TR199801782T2 (xx)	1998-12-21	Kinoksalindionlar
EA200000996A1 (ru)	2001-06-25	Конденсированные с арилом азаполициклические соединения
DE3575140D1 (de)	1990-02-08	Dreizyklische oxindole als antientzuendungsmittel.
RU95104939A (ru)	1996-10-27	Тетрациклические соединения, способ их получения и промежуточные соединения для этого и применение их в качестве противоопухолевых веществ
ID25477A (id)	2000-10-05	Turunan-turunan spiropiperidin
EP0604355A3 (en)	1995-02-08	Alkyl substituted heterocyclic compounds.
KR970703301A (ko)	1997-07-03	신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative)
ATE116974T1 (de)	1995-01-15	5- piperazinylalkyl-1,5-benzothiazepinone verwendbar als calciumantagonisten.
ATE151750T1 (de)	1997-05-15	3-(indol-3-yl) propensäurderivate, die als nmda- antagonisten nützlich sind
DE69001004D1 (de)	1993-04-08	Zusammensetzung gegen leberkrankheiten.
ATE125793T1 (de)	1995-08-15	Substituierte alkensäure und ihre derivate.
WO1997029077A1 (fr)	1997-08-14	Derives amides substitues